| Radiomics: from qualitative to quantitative imaging W Rogers, S Thulasi Seetha, TAG Refaee, RIY Lieverse, RWY Granzier, ... The British Journal of Radiology 93 (1108), 20190948, 2020 | 216 | 2020 |
| Lymphocyte-Sparing Radiotherapy: The Rationale for Protecting Lymphocyte-rich Organs When Combining Radiotherapy With Immunotherapy P Lambin, RIY Lieverse, F Eckert, D Marcus, C Oberije, AMA van der Wiel, ... Seminars in Radiation Oncology 30 (2), 187-193, 2020 | 69 | 2020 |
| Hypoxia PET imaging with [18F]-HX4—a promising next-generation tracer S Sanduleanu, AMA van der Wiel, RIY Lieverse, D Marcus, A Ibrahim, ... Cancers 12 (5), 1322, 2020 | 40 | 2020 |
| Human fibronectin extra domain B as a biomarker for targeted therapy in cancer RIY Lieverse, D Marcus, AMA van der Wiel, EJ Van Limbergen, J Theys, ... Molecular oncology 14 (7), 1555-1568, 2020 | 36 | 2020 |
| Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised … RIY Lieverse, EJ Van Limbergen, CJG Oberije, EGC Troost, SR Hadrup, ... BMC cancer 20, 1-10, 2020 | 32 | 2020 |
| Releasing the brakes of tumor immunity with anti-PD-L1 and pushing its accelerator with L19–IL2 cures poorly immunogenic tumors when combined with radiotherapy VO Pimentel, D Marcus, AMA van der Wiel, NG Lieuwes, R Biemans, ... Journal for immunotherapy of cancer 9 (3), 2021 | 27 | 2021 |
| Charged Particle and Conventional Radiotherapy: Current Implications as Partner for Immunotherapy D Marcus, RIY Lieverse, C Klein, A Abdollahi, P Lambin, LJ Dubois, ... Cancers 13 (6), 1468, 2021 | 26 | 2021 |
| Toxicity of L19-Interleukin 2 Combined with Stereotactic Body Radiation Therapy: A Phase 1 Study EJ Van Limbergen, A Hoeben, RIY Lieverse, R Houben, C Overhof, ... International Journal of Radiation Oncology* Biology* Physics 109 (5), 1421-1430, 2021 | 10 | 2021 |
| Will immunotherapy really change radiotherapy? P Lambin, R Lieverse The Lancet Oncology 20 (12), 1642-1644, 2019 | 2 | 2019 |
| Improving shared decision making for lung cancer treatment by developing and validating an open-source web based patient decision aid for stage I–II non-small cell lung cancer I Halilaj, A Ankolekar, A Lenaers, A Chatterjee, CJG Oberije, L Eppings, ... Frontiers in Digital Health 5, 1303261, 2024 | | 2024 |
| Charged particle and conventional radiotherapy D Marcus, RIY Lieverse, C Klein, A Abdollahi, P Lambin, LJ Dubois, ... | | 2021 |
| Toxicity of L19-Interleukin 2 combined with Stereotactic Body Radiation Therapy: A phase I study HA Limbergen Ej, R Lieverse, R Houben, C Overhof, L Jacobi, A Postma, ... International Journal of Radiation Oncology Biology Physics 109 (5), 1421-1430, 2021 | | 2021 |
| PO-1542 Integrating biomarker performance in sample size calculations for therapeutic trials C Oberije, R Lieverse, Y Van Wijk, L Dubois, A Van der Wiel, D Marcus, ... ESTRO 2020 152, 848 (S834), 2020 | | 2020 |
| OC-0084 Combining RT with L19-IL2 and aPDL1: from preclinical results towards a phase II trial (ImmunoSABR). R Lieverse, E Van Limbergen, V Olivo Pimentol, C Oberije, D Neri, ... ESTRO 2020 152, 51 (S38), 2020 | | 2020 |
| Improving Decision Making By Developing and Validating a Web Based Patient Decision Aid for Stage I-II Non-Small Cell Lung Cancer. I Halilaj, A Jochems, C Oberije, J van Timmeren, R Lieverse, P Lambin 41st Annual Meeting of the Society for Medical Decision Making, 2019 | | 2019 |
| SP-0687 Combining Radiotherapy with Immunotherapy: focus on immunocytokines P Lambin, R Lieverse, EJ Van Limbergen, VO Pimentel, D Marcus, ... Radiotherapy and Oncology 133, S358-S359, 2019 | | 2019 |
| Charged Particle and Conven-tional Radiotherapy: Current Impli-cations as Partner for Immunother-apy. Cancers 2021, 13, x D Marcus, RIY Lieverse, C Klein, A Abdollahi, P Lambin, LJ Dubois, ... cancer 20, e417-e433, 2019 | | 2019 |
Philippe LambinProfessor of Precision Medicine, Maastricht University & Scientist ULBVerified email at maastrichtuniversity.nl
